Natixis Neogenomics Inc Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Neogenomics Inc stock. As of the latest transaction made, Natixis holds 150 shares of NEO stock, worth $2,229. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 150
-0.0%
Holding current value
$2,229
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NEO
# of Institutions
292Shares Held
124MCall Options Held
698KPut Options Held
120K-
Black Rock Inc. New York, NY19.7MShares$292 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14MShares$209 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$102 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$98.1 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$97.2 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.87B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...